HER2 testing: current status and future directions.

Area of Science:

• Oncology
• Pathology
• Biomarker Detection

Background:

• Accurate human epidermal growth factor receptor 2 (HER2) status determination is crucial for effective breast cancer management.
• Established guidelines by the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) aim to standardize HER2 testing.
• Existing ASCO/CAP criteria might inadvertently exclude certain patient groups who could benefit from HER2-targeted therapies.

Purpose of the Study:

• To highlight the critical role of accurate HER2 testing in breast cancer treatment.
• To discuss the limitations of current ASCO/CAP guidelines in patient access to HER2-targeted therapy.
• To emphasize the ongoing review of ASCO/CAP guidelines and the need for research into advanced HER2 assessment techniques.

Main Methods:

• Review of current ASCO/CAP guidelines for HER2 testing.
• Analysis of potential limitations in existing criteria.
• Discussion of emerging techniques for HER2 status assessment.

Main Results:

• Current ASCO/CAP guidelines, while essential, may not encompass all patients who could benefit from HER2-targeted treatments.
• There is an ongoing effort by ASCO/CAP to revise guidelines for improved HER2 testing accuracy and inclusivity.
• Research into novel and reproducible methods for HER2 assessment is essential.

Conclusions:

• Optimizing breast cancer outcomes relies on accurate HER2 testing.
• ASCO/CAP guidelines are under review to enhance HER2 testing protocols and incorporate new technologies.
• Continued research is vital for developing precise and reliable HER2 assessment techniques to ensure optimal patient care.